Assessing Palatability of a New Amphetamine Extended-Release Tablet Formulation for the Treatment of ADHD
Open Access
- 1 July 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Drug Design, Development and Therapy
- Vol. ume 15, 2979-2985
- https://doi.org/10.2147/dddt.s309378
Abstract
Introduction/Objective: ADHD is, for many people, a lifelong disease that requires chronic medication use. Stimulant therapy is often recommended as first-line treatment for ADHD. Adherence to stimulant treatment among patients diagnosed with ADHD is poor. Major regulatory agencies have recommended measurement of palatability for new tablet formulations. A new amphetamine extended-release tablet (AMPH ER TAB) for the treatment of attention-deficit/hyperactivity disorder (ADHD) was developed. The AMPH ER TAB has a bubblegum flavor and can be chewed or swallowed whole. In 2016, the FDA developed a draft guidance document on the topic of chewable drug tablet formulation palatability. Methods: A palatability study of the AMPH ER TAB using the 2016 FDA guidance was conducted. Subjects were asked to assess the taste, aftertaste, and mouthfeel of the tablet formulation using a short questionnaire. Scores from the questionnaire were rated and presented. Results: The substudy assessed 35 subjects with a mean age of 38 (± 11) years. Subjects were predominantly male, non-Hispanic, and White. Most subjects rated the oral sensation/mouth feel and taste of the tablet as positive (pleasant to very pleasant) (70.1% and 83.6%, respectively). Additionally, 86.6% of the subjects rated the strength of the taste as neutral (moderate taste) or positive (mild to no taste). Finally, 82.1% of all subjects rated the aftertaste as positive (pleasant to very pleasant) and 92.5% of subjects rated the strength of the aftertaste as neutral or positive (mild to no taste). The trends in evaluation scores for each question were similar regardless of whether the ER chewable tablet was administered under fasted or fed conditions. Conclusion: The positive palatability data presented here will be useful for future “real-world” assessments of adherence to treatment with the AMPH ER TAB. Enhanced adherence may bolster the argument that taste, mouthfeel, and aftertaste are critical determinants of treatment adherence.Keywords
This publication has 19 references indexed in Scilit:
- Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder – a systematic literature reviewNeuropsychiatric Disease and Treatment, 2014
- Drug Treatment Patterns of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents in Germany: Results from a Large Population-Based Cohort StudyJournal of Child and Adolescent Psychopharmacology, 2012
- Evaluation of attitudes towards treatment in adolescents with attention deficit hyperactivity disorder (ADHD)European Child & Adolescent Psychiatry, 2012
- Prescribing for children – taste and palatability affect adherence to antibiotics: a reviewArchives of Disease in Childhood, 2011
- ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and AdolescentsPEDIATRICS, 2011
- Childhood Predictors of Adult Attention-Deficit/Hyperactivity Disorder: Results from the World Health Organization World Mental Health Survey InitiativeBiological Psychiatry, 2009
- Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity DisorderJournal of the American Academy of Child & Adolescent Psychiatry, 2007
- The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder.Journal of Abnormal Psychology, 2002
- The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder.Journal of Abnormal Psychology, 2002
- A Randomised, Single-blind, Crossover Comparison of the Acceptability of the Calcium and Vitamin D3 Supplements Calcichew D3 Forte® and Ad Cal D3® in Elderly PatientsCurrent Medical Research and Opinion, 2001